<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In order to elucidate the possibility of costimulatory molecules-mediated immuno or immuno-gene therapy for human <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, we analyzed 30 hematopoietic cell lines and cells obtained from 48 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> for the expression of costimulatory molecules such as CD80 and CD86 </plain></SENT>
<SENT sid="1" pm="."><plain>The 30 hematopoietic cell lines were composed of 4 cell lines derived from the patients with T-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e>), 3 from <z:e sem="disease" ids="C0856536" disease_type="Neoplastic Process" abbrv="">Philadelphia chromosome positive</z:e> ALL (Ph1+ALL), 8 from <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 3 from <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> (APL), 8 from <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> at <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> (<z:mp ids='MP_0005481'>CML</z:mp>-BC), 3 from Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and one from follicular cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The expression of CD80 or CD86 was frequent on cell lines derived from the patients with <z:mp ids='MP_0005481'>CML</z:mp>-BC or Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, while it was rare on cell lines from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Subsequently we analyzed the cells obtained from 48 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, which consisted of 6 samples from patients with ALL, 30 from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 2 from <z:mp ids='MP_0005481'>CML</z:mp>-BC, 3 from B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and one from each <z:hpo ids='HP_0011009'>acute</z:hpo> mixed <z:hpo ids='HP_0001909'>leukemia</z:hpo> (AMixL), adult T cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ATL), T-cell large granular lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (T-LGL <z:hpo ids='HP_0001909'>leukemia</z:hpo>), <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in T, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) or T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Among <z:hpo ids='HP_0000001'>all</z:hpo> the 48 cases, <z:hpo ids='HP_0000001'>all</z:hpo> cases except one case with CLL and two with B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were demonstrated to be negative for CD80 on the neoplastic cells </plain></SENT>
<SENT sid="5" pm="."><plain>CD86 and HLA-DR were shown to be expressed in 50% and 88% of total 48 cases respectively </plain></SENT>
<SENT sid="6" pm="."><plain>In 30 AML samples, CD86 was positive in 15 cases (50%), which was sharply in contrast with the finding that CD80 was not detected in any <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> samples </plain></SENT>
<SENT sid="7" pm="."><plain>HLA-DR was expressed in 25 AML samples (83%) </plain></SENT>
<SENT sid="8" pm="."><plain>We also treated seven human hematopoietic cell lines with IFN-gamma, IL-12 or IL-15 and observed whether these cytokines could induce or enhance the expression of CD40, CD54, CD58 and HLA-DR as well as CD80 and CD86 </plain></SENT>
<SENT sid="9" pm="."><plain>The present study demonstrated that the expression of CD86 could be upregulated not only by IFN-gamma, but also by IL-12 or IL-15 in some cell lines </plain></SENT>
<SENT sid="10" pm="."><plain>These findings suggested the possibility that the absence of CD80 on neoplastic cells may be associated with the lack of efficient anti-<z:e sem="disease" ids="C1519680" disease_type="Disease or Syndrome" abbrv="">tumor immunity</z:e> in most patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> and that the immuno or immuno-gene therapy manipulating the expression of costimulatory molecules such as CD80 may be a useful treatment modality for <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
</text></document>